Host: The Japanese Society of Toxicology
The development of biotechnology-derived pharmaceuticals (biopharmaceuticals) were initially developed in the early 1980s. It has been recognized that the selection of animal species is a crucial consideration in the safety assessment of biopharmaceuticals. Especially in the selection of animal species, monkeys are often used in non-clinical studies due to their cross-reactivity. However, simply crossing to the target molecule is not enough, and it is said that functional activity is important. I would like to discuss some points for nonclinical evaluation of biopharmaceuticals in monkeys.
